Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...